secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcadia Biosciences, Inc. (RKDA)
CIK:        0001469443
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066420
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcadia Biosciences Q1 net income $2.6M; Zola sales up 90%; Roosevelt deal amended to 90/10 split
--------------------------------------------------------------------------------

- Q1 2025 net income $2.6M ($1.90/share) vs net loss of $2.4M ($1.78 loss) in Q1 2024.
- Revenue $1.2M (+22% YoY) driven by Zola coconut water sales up 90% and distribution up 70%.
- Sold patent portfolios for $750K, eliminating $1M in liabilities; operating expenses near 10-year low.
- Amended Roosevelt merger: fixed equity split 90% to Roosevelt partners, 10% to Arcadia stockholders; expected close late summer.
- Cash and cash equivalents $3.16M, down from $4.24M at Dec 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1469443/000095017025066420/0000950170-25-066420-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1469443/000095017025066420/rkda-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066420

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer